相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients
Christina Yau et al.
LANCET ONCOLOGY (2022)
Management of Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
Sonia Pernas et al.
JCO ONCOLOGY PRACTICE (2021)
Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE
E. P. Mamounas et al.
ANNALS OF ONCOLOGY (2021)
Advances in Breast Cancer Radiotherapy: Implications for Current and Future Practice
Chirag Shah et al.
JCO ONCOLOGY PRACTICE (2021)
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Matthew J. Page et al.
BMJ-BRITISH MEDICAL JOURNAL (2021)
Risk-based decision-making in the treatment of HER2-positive early breast cancer: Recommendations based on the current state of knowledge
Christian Jackisch et al.
CANCER TREATMENT REVIEWS (2021)
Original Research Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial
Valentina Guarneri et al.
EUROPEAN JOURNAL OF CANCER (2021)
Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of Dual ERBB2 Blockade in Patients With ERBB2-Positive Breast Cancer A Secondary Analysis of the TRAIN-2 Randomized, Phase 3 Trial
Anna van der Voort et al.
JAMA ONCOLOGY (2021)
Evolving Trends in Surgical Management of Breast Cancer: An Analysis of 30 Years of Practice Changing Papers
Stephen Keelan et al.
FRONTIERS IN ONCOLOGY (2021)
HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade
Aleix Prat et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2020)
Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis
Laura M. Spring et al.
CLINICAL CANCER RESEARCH (2020)
Breast Cancer, Version 3.2020
William J. Gradishar et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2020)
Antiemetics: ASCO Guideline Update
Paul J. Hesketh et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer
Aranzazu Fernandez-Martinez et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Optimal duration of adjuvant trastuzumab in treatment of early breast cancer: a meta-analysis of randomized controlled trials
Saroj Niraula et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis
Everardo D. Saad et al.
LANCET ONCOLOGY (2019)
Prognostic Value of Residual Disease after Neoadjuvant Therapy in HER2-Positive Breast Cancer Evaluated by Residual Cancer Burden, Neoadjuvant Response Index, and Neo-Bioscore
Tessa G. Steenbruggen et al.
CLINICAL CANCER RESEARCH (2019)
Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
Sara M. Tolaney et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
F. Cardoso et al.
ANNALS OF ONCOLOGY (2019)
Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study
Sara A. Hurvitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer
Jens Huober et al.
EUROPEAN JOURNAL OF CANCER (2019)
Impact of Breast Cancer Subtypes on Prognosis of Women with Operable Invasive Breast Cancer: A Population-based Study Using SEER Database
Ki-Tae Hwang et al.
CLINICAL CANCER RESEARCH (2019)
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
G. von Minckwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
A gene expression signature of Retinoblastoma loss-of-function predicts resistance to neoadjuvant chemotherapy in ER-positive/HER2-positive breast cancer patients
Emanuela Risi et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer
Andreas Schneeweiss et al.
EUROPEAN JOURNAL OF CANCER (2018)
Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44)
Michael Untch et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial
Sara A. Hurvitz et al.
LANCET ONCOLOGY (2018)
Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial
Mette S. van Ramshorst et al.
LANCET ONCOLOGY (2018)
Neither fixed nor random: weighted least squares meta-regression
T. D. Stanley et al.
RESEARCH SYNTHESIS METHODS (2017)
Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype
W. Fraser Symmans et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial
Antonio Llombart-Cussac et al.
LANCET ONCOLOGY (2017)
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
Hongchao Pan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel
U. A. Nitz et al.
ANNALS OF ONCOLOGY (2017)
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab
S. Loibl et al.
ANNALS OF ONCOLOGY (2016)
Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial
M. V. Dieci et al.
ANNALS OF ONCOLOGY (2016)
Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib
Lisa A. Carey et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial
Luca Gianni et al.
LANCET ONCOLOGY (2016)
Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes A Meta-Analysis
Kristine R. Broglio et al.
JAMA ONCOLOGY (2016)
Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+operable breast cancer: 5-year outcomes of NSABP protocol B-41.
Andre Robidoux et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40-GeparQuattro)
G. von Minckwitz et al.
ANNALS OF ONCOLOGY (2014)
Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study
Aleix Prat et al.
CLINICAL CANCER RESEARCH (2014)
Molecular Features and Survival Outcomes of the Intrinsic Subtypes Within HER2-Positive Breast Cancer
Aleix Prat et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Patricia Cortazar et al.
LANCET (2014)
Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort
Luca Gianni et al.
LANCET ONCOLOGY (2014)
Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)
A. Schneeweiss et al.
ANNALS OF ONCOLOGY (2013)
Multicenter Phase II Study of Neoadjuvant Lapatinib and Trastuzumab With Hormonal Therapy and Without Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer: TBCRC 006
Mothaffar F. Rimawi et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
Gunter von Minckwitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2-Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study
Valentina Guarneri et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
Jose Baselga et al.
LANCET (2012)
Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial
Michael Untch et al.
LANCET ONCOLOGY (2012)
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
Luca Gianni et al.
LANCET ONCOLOGY (2012)
Pathologic Complete Response After Neoadjuvant Chemotherapy Plus Trastuzumab Predicts Favorable Survival in Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer: Results From the TECHNO Trial of the AGO and GBG Study Groups
Michael Untch et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31
Edith A. Perez et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Adjuvant Trastuzumab in HER2-Positive Breast Cancer
Dennis Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Neoadjuvant Treatment With Trastuzumab in HER2-Positive Breast Cancer: Results From the GeparQuattro Study
Michael Untch et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort
Luca Gianni et al.
LANCET (2010)
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
MJ Piccart-Gebhart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
EH Romond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
分享论文
